September 21, 2021
Ionis Pharmaceuticals has a 30-year track record of perfecting and advancing RNA-targeted drug discovery and development and is now expanding its commercialization capabilities. That expansion led to the placement of Dr. Shay Bujanover as the company’s first Vice President of Medical Affairs. Dr. Bujanover has held roles of increasing responsibility in business development and marketing and has been focused on Medical/Clinical Affairs for more than ten years. Ionis will benefit from his proven track record of quickly mastering new therapeutic areas, building/leading high performing teams, and working cross-functionally and with external stakeholders to successfully execute product launches, educate on existing clinical data, and develop new data. The Chase Group congratulates Ionis on the addition of Dr. Bujanover to their leadership team. If you seek a strong partnership with your executive search firm, we welcome the opportunity to work with you. Let us help you build your leadership team and experience the impact The Chase Group can have on your company’s success/growth. To learn more, email karen@chasegroup.com.
